Regeneron drug shows muscle preservation in GLP-1 weight loss trial
Tweet Send to a Friend
Regeneron Pharmaceuticals (NASDAQ: REGN) announced results from its Phase 2 COURAGE trial showing that trevogrumab, an anti-myostatin antibody, preserved lean ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




